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Summary
 
Protective immunity to infection by many intracellular pathogens requires recognition by cy-
totoxic T lymphocytes (CTLs) of antigens presented on major histocompatibility complex
(MHC) class I molecules. To be presented for recognition by pathogen-specific CTLs, these
antigens must gain access to the host cell class I processing pathway. In the case of intracellular
bacterial pathogens, the majority of bacterial proteins are retained within the bacterial mem-
brane and therefore remain inaccessible to the host cell for antigen processing. We have iso-
lated a CTL clone from a C57BL/6 mouse infected with the intracellular gram-positive bacte-
 
rium 
 
Listeria monocytogenes
 
 (LM) and have identified the source of the
 
 
 
antigen. Using a genomic
expression library, we determined that the clone recognizes an antigenic 
 
N
 
-formyl peptide pre-
sented by the nonpolymorphic murine MHC class Ib molecule, H2-M3. Several lengths of this
peptide were able to sensitize cells for lysis by this CTL clone. The source of this antigenic
peptide is a 23–amino acid polypeptide encoded at the start of a polycistronic region. Analysis
of mRNA secondary structure of this region suggests that this polypeptide may be a leader pep-
tide encoded by a transcriptional attenuator.
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I
 
ntracellular pathogens, including viruses and bacteria
such as 
 
Mycobacterium tuberculosis
 
,
 
 Salmonella typhimurium
 
,
and
 
 Listeria monocytogenes
 
 (LM),
 
1
 
 are major causes of infec-
tious diseases. As they grow and replicate within permissive
host cells, they are protected from the humoral immune re-
sponse (1, 2). However, infected cells can be recognized
and destroyed by CD8
 
1
 
 CTLs (3). This population of ef-
fector cells prevents the replication and spread of the
pathogen and allows for clearance by other immune effec-
tors, such as antibodies or nonpermissive phagocytic im-
mune cells.
CD8
 
1
 
 CTLs recognize antigens that are produced by the
infecting organism and then processed by the host cell and
presented by MHC class I molecules. Pathogen-derived
proteins able to access the cytosol are degraded into pep-
tides by proteasomes and transported via the transporter as-
sociated with antigen processing into the endoplasmic
reticulum, where they associate with nascent class I mole-
cules. In viral infections, host cell ribosomes are used for
protein production; therefore, viral proteins are directly ex-
posed to the class I processing pathway. However, bacterial
proteins are produced within the bacterial membrane and
are sequestered from the host cell cytosol. Thus, the bacte-
rial products available for presentation by MHC class I
molecules are confined to those that are secreted or shed by
the bacteria (4). To understand which antigens are able to
elicit CTL-mediated immune responses to intracellular
bacteria, it is necessary to identify those molecules that en-
ter the host cell cytosol and, therefore, the MHC class I
processing pathway.
The MHC class I molecules are divided into two sub-
groups: the polymorphic class Ia molecules, which present
peptides of eight or nine amino acids in length, and the
nonpolymorphic class Ib molecules, which present peptides
as well as nonpeptide ligands (5). Two of these MHC class
Ib molecules are thought to have evolved to present hydro-
phobic antigens derived from intracellular bacterial patho-
gens (6, 7). Human CD1, for example, is known to bind
and present several glycolipid moieties derived from myco-
bacterial cell wall components (8, 9). The murine class Ib
molecule, H2-M3, has a high affinity for peptides that con-
tain an 
 
N
 
-formyl methionine as the NH
 
2
 
-terminal amino
acid (10, 11). In prokaryotes, the initial methionine of each
 
1
 
Abbreviations used in this paper:
 
 BHI, brain heart infusion broth; CHO,
Chinese hamster ovary; LLO, listeriolysin O; LM, 
 
Listeria monocytogenes
 
;
MOI, multiplicity of infection; ORF, open reading frame; rmu, recombi-
nant murine; sf, serum-free
 
.
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protein is formylated. In eukaryotes, only proteins from
mitochondria and chloroplasts initiate with 
 
N
 
-formyl me-
thionine. Therefore, H2-M3 preferentially presents anti-
gens derived from intracellular bacteria (12).
The gram-positive bacterium LM is an intracellular
pathogen that infects hepatocytes, endothelial cells, and
permissive (nonbacteriocidal) macrophages. Upon infec-
tion of the host cell, secretion by LM of the hemolysin lis-
teriolysin O (LLO) results in lysis of the phagosomal mem-
brane and entry of the bacteria into the host cell cytosol
(13). This cytosolic localization facilitates entry of antigenic
molecules released from the bacteria into the host cell class I
processing pathway (14). Thus, LM is well suited for the
study of MHC class I–restricted presentation of antigens
derived from intracellular bacterial pathogens (15).
CD8
 
1
 
 CTLs are necessary for protective immunity
against infection with LM (16, 17). Adoptive transfer of
spleen cells from mice immunized with a sublethal dose of
LM confers protection to naive animals (18–20). In some
cases, immunity can be transferred between mice of dispar-
ate MHC haplotypes, suggesting antigen presentation by
nonpolymorphic MHC molecules (21, 22). Subsequent
studies have demonstrated that H2-M3 is able to present
LM antigens to CTL clones isolated from LM-infected
mice (6, 23). To date, two LM-derived peptides presented
by H2-M3 have been identified. One is a pentapeptide that
was identified by tandem mass spectrometry of LM bacte-
rial culture supernatant preparations (24). It has the se-
quence f-MIVIL, and the protein from which it is derived
has not yet been identified. The sequence of the second
peptide was elucidated by screening an LM genomic ex-
pression library for production of antigenic activity (25).
Genomic inserts coding for activity were sequenced, and a
peptide of six or seven amino acids in length with the se-
quence f-MIGWII(A) was identified as the active peptide.
A novel membrane protein, called LemA, was identified as
the source of the MIGWII(A) peptide.
Since antigenic peptides presented by MHC class I mol-
ecules are derived generally from cytosolic proteins, it
would be expected that bacterial products that efficiently
gain access to the host cell cytosol would be preferentially
presented (4). LM resides in the host cell cytosol, and in-
deed, all of the identified peptides from LM that are pre-
sented by MHC class Ia molecules are products of secreted
proteins. Four epitopes presented on the murine class Ia
H-2K
 
d
 
 molecule have been identified. They are derived
from LLO (26), p60 (27, 28), and a metalloprotease (29), all
of which are proteins secreted by LM. The protein source
of the f-MIVIL peptide is unknown; however, it is present
in bacterial culture supernatants, indicating that it is se-
creted or shed by the bacteria (23, 24). LemA is believed to
be a bacterial membrane protein with an N
 
out
 
–C
 
in
 
 topol-
ogy; thus, the H2-M3–presented epitope is on the outside
surface of the bacterial membrane and is exposed to the
host cell cytosol. Identification of additional bacterial anti-
gens presented by MHC class I molecules and the proteins
from which they are derived will establish whether expo-
sure to the host cell cytosol is a common feature shared by
these antigens. In addition, characterization of the nature
and source of antigenic peptides presented by nonpolymor-
phic MHC class Ib molecules may enable the development
of vaccine strategies that circumvent the problem of MHC
restriction encountered in outbred populations.
In this study, we describe an LM-derived 
 
N
 
-formyl pep-
tide presented by H2-M3. Using a genomic LM expression
library, we determined the sequence of this peptide. Sev-
eral lengths of this peptide are recognized by an H2-M3–
restricted CTL clone, with the hexameric peptide having
activity at concentrations in the femtomolar range. In addi-
tion, we have determined that this peptide is derived from
a 23–amino acid leader polypeptide. This polypeptide is
encoded at the start of a polycistronic mRNA region and
may be a by-product of transcriptional attenuation.
 
Materials and Methods
 
Mice and Cell Lines.
 
C57BL/6, BALB/c, and DBA/2 mice
were purchased from The Jackson Laboratory (Bar Harbor, ME).
Cell lines were cultured at 37
 
8
 
C in 7% CO
 
2
 
 in IMDM (Sigma
Chemical Co., St. Louis, MO) supplemented with 5 mM Hepes,
2 mM glutamine, 1 mM hydroxypyruvate, 50 mM 2-mercapto-
ethanol, nonessential amino acids, 100 IU/ml penicillin, 100
mg/ml streptomycin, 50 mg/ml gentamycin, and 10% fetal bo-
vine serum (cIMDM; Intergen Co., Purchase, NY). Serum-free
IMDM (sfIMDM) is identical to cIMDM in formulation, except
BSA (Sigma Chemical Co.) 0.5% (wt/vol) was substituted for
fetal bovine serum as a source of protein. BMC2.3 is a C57BL/
6-derived H-2
 
b
 
 macrophage–like cell line obtained from Dr. Ken-
neth Rock (Harvard University, Boston, MA). EL4 is a C57BL/6-
derived H-2
 
b
 
 thymoma cell line. P815 is a DBA/2-derived H-2
 
d
 
mastocytoma cell line. M12.C3 is a BALB/c-derived H-2
 
d
 
 lym-
phoma cell line. MC.12 is an H-2
 
d
 
 macrophage–like cell line.
SVCAS2F6 is a fibroblast cell line that expresses a mutant (null)
allele of H2-M3, and 13S2 is the SVCAS2F6 line that has been
transfected with a chimeric MHC class I molecule containing the
cytoplasmic, transmembrane, and 
 
a
 
3
 
 domains from H-2L
 
d
 
 and
the 
 
a
 
1
 
 and 
 
a
 
2
 
 domains from wild-type H2-M3 (30). L9.6 is a
C57BL/6 
 
3
 
 BALB/c F
 
1
 
–derived CD8
 
1
 
 CTL clone that recog-
nizes the murein hydrolase p60 epitope 217-225 presented by
H-2K
 
d
 
 and obtained from Dr. Eric Pamer (Yale University, New
Haven, CT). Recombinant murine GM-CSF (rmuGM-CSF)
was produced from cultured Chinese hamster ovary (CHO) cells
transfected with the murine GM-CSF gene (gift of Dr. Steven
Dow, National Jewish Medical and Research Center, Denver,
CO). Approximately 2–5 
 
3
 
 10
 
6
 
 CHO/GM-CSF cells were cul-
tured in 100 ml cIMDM in 75 cm
 
2
 
 tissue culture flasks for 4–5 d
at 37
 
8
 
C in 7% CO
 
2
 
. Culture supernatant was harvested and used
as a source of rmuGM-CSF for culture of primary bone marrow
macrophages. Primary bone marrow macrophages were grown in
six-well tissue culture plates in 5 ml cIMDM/well supplemented
with 8% rmuGM-CSF/CHO cell culture supernatant.
 
Peptide Synthesis.
 
Peptides were synthesized using standard
solid phase Fmoc chemistry on a peptide synthesizer (model
433A; Applied Biosystems, Foster City, CA). Protecting groups
were removed from resin-bound amino acid residues using hy-
drogen fluoride. Fmoc amino acids were purchased from
AnaSpec, Inc. (San Jose, CA), and 
 
N
 
-formyl methionine was 
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purchased from Bachem Bioscience Inc. (King of Prussia, PA).
Peptides were purified by reverse-phase HPLC on a Luna 10
 
m
 
C18(2) 250 
 
3
 
 2.12 mm column (Phenomenex, Inc., Torrance,
CA) using an HPLC pump (model 510; Waters Associates, Mil-
ford, MA). Integrity of the peptides was confirmed using a Voy-
ager reverse-phase matrix-assisted laser desorption ionization
time-of-flight mass spectrometer (PerSeptive Biosystems, Framing-
ham, MA). Peptides were dissolved in 100% DMSO, aliquoted, and
stored at 
 
2
 
20
 
8
 
C. Stock solutions were diluted in PBS as needed.
 
CTL Clones and Assays.
 
CTL clones were generated by im-
munizing 8–10-wk-old female C57BL/6 mice i.p. with 10
 
4
 
 CFU
LM (serotype 1/2a). Spleen and lymph node cells were harvested
on day 8 after infection. Erythrocytes were lysed with Tris-buf-
fered ammonium chloride (Sigma Chemical Co.), and spleen and
lymph node cells were cultured in flat-bottomed 24-well plates in
2 ml cIMDM/well. Spleen and lymph node cells, 2 
 
3
 
 10
 
5
 
/well,
were restimulated with 2 
 
3
 
 10
 
4
 
 irradiated (18,000 rads) LM-
infected MC.12 or BMC2.3 cells/well in the presence of 4 
 
3
 
 10
 
6
 
irradiated (3,000 rads) C57BL/6 spleen cells/well. The MC12
and BMC2.3 cell lines were infected with LM at a multiplicity of
infection (MOI) of 10:1 for 3 h before establishing the restimula-
tion culture. Responder cells were cloned by limiting dilution in
flat-bottomed 96-well plates after 1 wk in culture. CTL clones
were restimulated every 7–8 d in 24-well plates and cultured in
cIMDM supplemented with 4% supernatant from concanavalin
A–stimulated rat spleen cells.
Target cells were labeled with [
 
51
 
Cr]NaCr
 
2
 
O
 
4
 
 for 1–1.5 h.
Target cells that were to be infected with LM were cultured in
antibiotic-free cIMDM for a minimum of 72 h before assay. LM
from a log phase culture were washed three times in PBS, then
added to target cells at an MOI of 10:1. Gentamycin sulfate
(Sigma Chemical Co.) at a final concentration of 10 
 
m
 
g/ml was
added 30 min after infection to kill extracellular bacteria. LM cul-
ture supernatants and peptides were incubated with target cells for
1–2 h at 37
 
8
 
C before addition of effectors. Peptide titration
curves for 
 
N
 
-formyl and nonformylated peptides were performed
in sfIMDM to eliminate peptide degradation by serum proteases.
CTL assays were performed in 96-well round-bottomed plates.
Target cells were plated at 10
 
4
 
 cells/well in 100 
 
m
 
l cIMDM, and
CTLs were added at the indicated E/T ratio in 100 
 
m
 
l cIMDM.
Plates were centrifuged for 3 min at 800 
 
g
 
, then incubated for 4 h
at 37
 
8
 
C in 7% CO
 
2
 
. Plates were centrifuged for 3 min at 1,500 
 
g
 
,
and 100 
 
m
 
l of medium/well was collected and counted for 1 min
on an automatic 
 
g
 
 counter. All assays were performed in tripli-
cate. Spontaneous release was determined from wells containing
target cells in cIMDM with no effector cells. Total release was
determined from wells containing target cells in cIMDM plus 1%
Triton-X 100 (Sigma Chemical Co.) without effector cells. Per-
cent specific release was calculated as follows: [(cpm released in
the presence of effector cells 
 
2
 
 cpm of nonspecific release)/(cpm
of total release 
 
2
 
 cpm of nonspecific release)] 
 
3
 
 100.
 
Culture of LM and E. coli Containing the LM Genomic Library.
 
The virulent LM strain used in these studies was EGD serotype
1/2a. LM were cultured in brain heart infusion broth (BHI;
Difco Laboratories Inc., Detroit, MI) at 37
 
8
 
C on a rotary shaker
at 200 rpm. The LM genomic expression library was the gift of
L.L. Lenz and M.J. Bevan (University of Washington, Seattle,
WA), and its construction has been described previously (25). In-
dividual LM genomic clones in 
 
E. coli
 
 DH10
 
b
 
 were grown in 0.2 ml
of BHI supplemented with 100 
 
m
 
g/ml spectinomycin in 96-well
flat-bottomed plates at 37
 
8
 
C for 24 h. Bacteria were lysed by
three rounds of freezing at 
 
2
 
80
 
8
 
C and thawing at 37
 
8
 
C. Bacterial
lysate was added at 10% to individual wells containing 
 
51
 
Cr-labeled
BMC2.3 for 1 h, then CTLs were added at an E/T ratio of 5:1.
Target cells were assayed for specific lysis as described. All positive
transformants identified were grown in 3 ml BHI for 24 h and re-
tested to confirm the presence of antigen. It was found during
these experiments that incubation of target cells with bacterial ly-
sates substantially increased the spontaneous release. Supernatants
from positive cultures contained levels of antigenic activity com-
parable with bacterial lysates, but were less toxic to the target
cells. After the initial round of screening, transformed bacteria
were no longer subjected to freeze-thawing, and culture superna-
tants were tested directly in 
 
51
 
Cr release assays.
 
DNA Sequencing and PCR Screening.
 
Restriction mapping of
plasmid DNA from positive transformants was performed using
restriction endonucleases from Promega Corp. (Madison, WI) ac-
cording to the manufacturer’s instructions. LM genomic DNA
was sequenced initially using the M13 forward primer 5
 
9
 
-
GTAAAACGACGGCCAG and the M13 reverse primer 5
 
9
 
-
CAGGAAACAGCTATGAC. Sequencing data thus generated
were used to design additional sets of internal sequencing primers.
All sequencing was performed at the National Jewish Medical and
Research Center core sequencing facility by dye terminator cycle
sequencing on a DNA sequencer (ABI Prism 377; Perkin-Elmer
Corp., Norwalk, CT).
Sequencing data were used to design PCR primer pairs that
would produce overlapping DNA fragments from the genomic
LM DNA insert. These PCR products were ligated directly into
the pCR 2.1 cloning vector (Invitrogen Corp., Carlsbad, CA) ac-
cording to the manufacturer’s instructions and transformed into
DH5
 
a
 
 
 
E. coli
 
. Transformants were grown in 200 
 
m
 
l BHI with 50
 
m
 
g/ml ampicillin (Sigma Chemical Co.) at 37
 
8
 
C for 24 h, and su-
pernatants were screened for antigenic activity in a standard 
 
51
 
Cr
release assay as described for the LM genomic expression library.
The PCR primer pair 5
 
9
 
-AAGCAGAGAAAAAATGTC and 5
 
9
 
-
CAAACGTCATTCCGGTATT amplifies a 1.64-kb insert with
antigenic activity from genomic clones H6.1 and E11.4. PCR
primers 5
 
9
 
-ACGATAGTCACAAACCGTG and 5
 
9
 
-ACACAA-
TGAAAACACCCC produce a 270-bp fragment, and primers
5
 
9
 
-TTTAATGATTGTAACGTTA and 5
 
9
 
-AAATTACATA-
CATCCCCA produce a 330-bp fragment, that both encode an-
tigenic activity and overlap by 60 bp.
 
Results and Discussion
 
CTL Clone C10.4 Recognizes a Listeria Peptide Presented
by H2-M3. Previous studies have shown that CTLs de-
rived from mice immunized with a sublethal dose of LM
are able to lyse target cells infected with LM and, in some
cases, target cells exposed to supernatant from LM cultures
(3, 23). To generate LM-specific CTL clones restricted by
nonpolymorphic MHC class Ib molecules, spleen and
lymph node cells from LM-infected C57BL/6 (H-2b) mice
were restimulated in vitro using an allogeneic (H-2d) mac-
rophage–like cell line infected with LM. Cell lines derived
from spleen and lymph node cells were tested for their abil-
ity to selectively lyse LM-infected target cells in a standard
51Cr release cytotoxicity assay. Cell lines able to lyse LM-
infected allogeneic macrophage–like target cells were iden-
tified and cloned by limiting dilution. The CTL clone
C10.4, isolated from the lymph nodes of an LM-infected
mouse, was selected because of its ability to specifically lyse
both syngeneic and allogeneic macrophage–like cell lines1714 H2-M3 Presentation of a Listeria Leader Peptide
infected in vitro with LM. In addition, C10.4 was found to
lyse the syngeneic macrophage–like cell line BMC2.3 ex-
posed to LM culture supernatant, but not BMC2.3 incu-
bated with uninoculated culture medium (Fig. 1 A). Using
LM culture supernatant as a source of antigen, we estab-
lished that C10.4 was able to lyse target cells of diverse
MHC haplotypes. Target cells from H-2b, H-2d, and H-2q
mice incubated with LM culture supernatant were lysed by
C10.4 (Fig. 1, A–D). This lack of MHC class Ia restriction
suggested two possibilities: that antigen presentation was
MHC class Ia permissive or that presentation was MHC
class Ib restricted.
The murine MHC class Ib molecule H2-M3 has been
shown to present LM-derived peptides containing an
N-formyl methionine residue to CD81 CTLs (23). Although
H2-M3 is highly conserved among most mouse strains, a
null allele from Mus musculus castaneus, which is unable to
present antigen for recognition by H2-M3–restricted CTLs,
has been described (31). A fibroblast cell line derived from
the B10.CAS2 mouse, which carries this null allele, is un-
able to present antigens to CTLs restricted by H2-M3. The
ability of this cell line to present H2-M3–restricted antigens
is restored by transfection with a chimeric MHC class I
molecule consisting of the a1 and a2 domains of wild-type
H2-M3 and the a3 transmembrane and cytoplasmic do-
mains of H-2Ld (30). To determine whether H2-M3 was
the presenting molecule, both transfected and untransfected
B10.CAS2 fibroblasts were incubated with LM culture su-
pernatant. The C10.4 CTL clone was able to kill B10.CAS2
cells transfected with the chimeric H2-M3wt gene, but did
not kill the untransfected cells (Fig. 2, A and B). Thus, the
H2-M3 molecule presents the antigen from the LM culture
supernatant to C10.4. Further biochemical analysis, includ-
ing protease digestion of LM culture supernatant, indicated
that the antigen presented by H2-M3 was proteinaceous
(data not shown).
Two LM-derived N-formyl peptides presented by H2-
M3 to LM-specific CTL clones have been described (24,
25). Neither of these peptides was able to sensitize cells for
lysis by C10.4. These peptides were also examined for their
ability to competitively inhibit the antigenic activity
present in LM culture. Both peptides had a half-maximal
inhibitory concentration (IC50) of z10 nM when mixed
with LM culture supernatant and tested for the ability to
sensitize EL4 target cells for lysis by C10.4 (data not
shown). Thus, the N-formyl LM peptides and the antigen
recognized by C10.4 were presented by the same MHC
class I molecule.
Isolation of Antigenic Activity Using an LM Genomic Li-
brary. The antigen recognized by C10.4 was identified by
screening an LM genomic expression library for antigenic
activity. Construction of this library has been described
previously (25). The library consists of approximately six
LM genome equivalents cloned as 5–8-kb inserts into the
plasmid expression vector pAT29 and transformed into
DH10b  E. coli. The library was screened by testing super-
natant from individual E. coli transformants for the ability to
sensitize BMC2.3 target cells for lysis by C10.4. Of 2,400
genomic clones tested, two positives were selected for fur-
ther analysis. Plasmid DNA from these positive transfor-
mants was isolated and subjected to digestion with restric-
tion endonucleases. Restriction maps of these two clones
suggested they were overlapping (data not shown). These
two LM DNA inserts were sequenced, and the sequence
data were compared for homology. We found that the en-
tire insert designated H6.1 was contained within the se-
quence of the insert designated E11.4 (Fig. 3).
Figure 1. Clone C10.4 recognizes LM antigen present in bacterial cul-
ture supernatant in an MHC class Ia–unrestricted manner. (A) The mac-
rophage-like cell line BMC2.3 (H-2b) presents antigen to CTL clone
C10.4 when infected in vitro with live washed LM (open circles), MOI 10:1.
BMC2.3 are also lysed when incubated with supernatant from LM cul-
tures (open triangles). Target cells from mice with different MHC haplo-
types were incubated with 48-h LM culture supernatant and then assayed
for lysis by C10.4. Primary bone marrow macrophages from (B) DBA/1
(H-2q) were lysed in the presence of LM culture supernatant but not
when incubated with uninoculated culture medium (open squares). The
H-2d B cell lymphoma cell line M12C3 (C) and the H-2d mastocytoma
cell line P815 (D) were lysed only in the presence of LM culture superna-
tant.
Figure 2. Antigen presentation to C10.4 is restricted by H2-M3. The
ability of C10.4 to lyse fibroblasts expressing mutant H2-M3cas2 or H2-
M3wt in the presence of LM culture supernatant was tested. (A) Untrans-
fected B10.CAS2 fibroblasts expressing the mutant H2-M3cas2 MHC class
I molecule were incubated with LM culture supernatant (open triangles) or
uninoculated culture medium (open squares) as a negative control. The fi-
broblast target cells were then assayed for lysis by C10.4. (B) B10.CAS2
fibroblasts transfected with the H2-M3wt MHC class I molecule were in-
cubated with LM culture supernatant or uninoculated culture medium as
in A, then assayed for lysis by C10.4.1715 Princiotta et al.
Using these sequence data, PCR primers were designed
to amplify DNA fragments of 1.5–2.0 kb from the LM in-
serts. These DNA fragments were designed to overlap each
other by 100–200 bp and to cover the entire sequence of
both LM inserts. It was found that when these PCR prod-
ucts were ligated directly into the pCR2.1 cloning vector
and transformed into DH5a E. coli, some of them pro-
duced antigenic activity that could be recovered from bac-
terial culture supernatant (data not shown). These culture
supernatants were screened to identify PCR products en-
coding antigenic activity. The sequences of PCR products
encoding activity were then used to produce a second set
of PCR products 200–400 bp in length that overlapped by
50–80 bp. In this way, two DNA fragments with antigenic
activity and overlapping by 60 bp were isolated from the
H6.1 and E11.4 inserts (Fig. 3).
Identification of an Antigenic N-formyl Peptide. Based on the
data presented above and the fact that the presenting mole-
cule is H2-M3, we expected that the antigenic peptide
would contain an N-formyl methionine residue. The 60-bp
insert was examined in all six reading frames for possible
ATG or GTG translation start sites. One open reading
frame (ORF) containing an ATG start site followed by sev-
eral hydrophobic residues was identified. The full-length
sequence of this ORF encodes a 23–amino acid polypep-
tide we have termed AttM. Since H2-M3 has a strong pref-
erence for hydrophobic peptides containing an N-formyl
methionine (11, 32, 33), this sequence was a likely candi-
date to encode the antigenic peptide recognized by C10.4.
The heptameric peptide encoded by the first 21 bp of this
sequence was synthesized and found to contain antigenic
activity at micromolar peptide concentrations (Fig. 4).
H2-M3 is able to present peptides of different lengths for
recognition by the same T cell clone (11, 25). Therefore,
the 5-, 6-, 7-, 8-, and 9-mer versions of the peptide were
synthesized and assayed for their ability to sensitize EL4
cells for lysis by C10.4. The 6-mer was found to have the
greatest activity, with half-maximal lysis of EL4 occurring
at concentrations of z80 fM (Fig. 4). Higher concentra-
tions of the longer peptides were required to sensitize EL4
cells for lysis by C10.4. Eliminating the sixth residue, phe-
nylalanine, almost completely abrogated recognition by
C10.4. Previous studies have shown that H2-M3 is able to
bind N-formyl peptides of five amino acids or shorter with
high affinity (34), suggesting that the phenylalanine at posi-
tion 6 of this peptide is crucial for TCR interaction with
the H2-M3–peptide complex.
When target cells were incubated with the 8- or 9-mer
peptides in the presence of fetal bovine serum, lower con-
centrations of peptide were required for half-maximal lysis,
suggesting that the bovine serum contained peptidase activ-
ity that cleaved the COOH-terminal end of the peptides.
The crystal structure of H2-M3 elucidated by Wang et al.
(33) demonstrates that the COOH-terminal residues of
bound peptides extend beyond the peptide binding groove
and suggests that COOH-terminal trimming of peptides
Figure 3. Strategy for cloning DNA fragments with antigenic activity
from an LM genomic library. Using sequence data from LM genomic
DNA inserts E11.4 and H6.1, PCR primers were designed to produce
overlapping fragments of 1.5–2.0 kb. A 1.64-kb fragment was found with
activity. PCR primers were designed to produce overlapping fragments
contained within the 1.64-kb sequence. These PCR products were de-
signed to be of 200–400 bp in length. Two fragments with a 60-bp over-
lap were found with activity. Sequence information from this 60-bp fragment
was used to identify a 23–amino acid polypeptide containing an N-formyl
methionine with antigenic activity.
Figure 4. Several lengths of an N-formyl peptide
target cells for lysis by C10.4. Peptides beginning
with the NH2-terminal methionine of the 23–
amino acid polypeptide identified from the ge-
nomic LM library were synthesized and tested for
antigenic activity. C10.4 cells were assayed for the
ability to lyse EL4 target cells coated with peptide at
an E/T of 5:1. Target cells were incubated for 1–2 h
at 378C in sfIMDM to prevent digestion of peptide
by serum-derived proteases. N-formyl peptides of
five (open squares), six (filled squares), seven (open cir-
cles), eight (filled circles), and nine (open triangles)
amino acids in length were found to have activity.
Peptides were titrated and tested for activity. The
6-mer retained activity at lower peptide concentra-
tions than the other N-formyl peptides tested. A
nonformylated 8-mer peptide (filled triangles) re-
quired a 105 higher concentration for half-maximal
lysis compared with the N-formyl 8-mer peptide. 
1716
 
H2-M3 Presentation of a 
 
Listeria
 
 Leader Peptide
 
could occur after binding of the peptide to H2-M3. Elimi-
nation of the 
 
N
 
-formyl moiety from peptides presented by
H2-M3 results in a 10
 
2
 
–10
 
4
 
-fold increase in the peptide
concentration needed for half-maximal lysis by CTLs spe-
cific for the 
 
N
 
-formyl peptide (25, 35). Compared with the
 
N
 
-formyl 8-mer peptide, 
 
z
 
10
 
5
 
-fold more of the non-
formylated 8-mer peptide was required for half-maximal
cell lysis by C10.4 (Fig. 4). Therefore, the ability of the
peptide to bind H2-M3 is highly dependent on the 
 
N
 
-formyl
moiety.
 
AttM is Encoded at the Transcriptional Start Site of a Polycis-
tronic Region.
 
To better understand the nature of the
AttM polypeptide, we examined the DNA sequence data
obtained from the H6.1/E11.4 LM genomic inserts. We
found that the region immediately upstream of the 
 
attM
 
translation start site contained a consensus sequence for an
RNA polymerase binding site (
 
2
 
35), a Pribnow box
(
 
2
 
10), and a ribosome binding site (Fig. 5). Examination of
the sequence data downstream from the polypeptide cod-
ing region revealed a polycistronic region containing at
least three ORFs. ORF 1 contains a ribosome binding site
consensus sequence immediately 5
 
9
 
 to the translation start
site (Fig. 5), as do ORF 2 and ORF 3 (GenBank accession
number AF039207). The presence of these sites is consis-
tent with the AttM polypeptide being a transcription start
site of a polycistronic operon.
The amino acid sequence of the three ORFs as well as
the AttM polypeptide were examined for sequence homol-
ogy with proteins of known sequence using the basic local
alignment sequence tool (BLAST) at the National Center for
Biotechnology Information (http://www.ncbi.nlm.nih.gov).
No significant homology was found for either the AttM
polypeptide or for ORF 1. ORF 2 was found to have sig-
nificant sequence homology (
 
P
 
 ,
 
10
 
2
 
12
 
) with members of
the XylS/AraC family of transcriptional regulatory proteins
(36, 37). Members of this protein family possess a COOH-
terminal region which contains a DNA binding motif that
is highly conserved. The NH
 
2
 
-terminal portion is not con-
served and is presumed to bind effector molecules that de-
termine specificity. ORF 3 had significant homology (
 
P
 
,
 
10
 
2
 
10
 
) with several bacterial NADH-dependent dehy-
drogenases. In fact, a region homologous to ORFs 2 and 3
and with similar orientation and spacing is present in the
 
yisR
 
 and the 
 
yisS
 
 genes of 
 
Bacillus subtilis
 
 (GenBank acces-
sion number Y09476 [38]). Therefore, these ORFs may be
part of a functional operon conserved in other gram-posi-
tive bacteria.
 
AttM Is a Candidate for a Leader Peptide Encoded by a Tran-
scriptional Attenuator.
 
The role of transcriptional attenua-
tors in the regulation of the expression of genes involved in
the biosynthesis of amino acids, nucleotides, and metabolic
enzymes has been well documented for prokaryotes, eu-
karyotes, and viruses (39–41). A common feature of these
transcriptional attenuators is the formation of stable second-
ary mRNA structure at the transcriptional start site of the
operon. Formation of this secondary structure prevents ri-
bosome binding and thus translation of the first ORF of the
operon. The formation of secondary mRNA structure can
be prevented if the ribosome stalls during translation of the
attenuator region of the operon, allowing the binding of ri-
bosomes to the downstream ORFs and translation. In all of
the transcriptional attenuators studied to date, the attenua-
tor leader region encodes a short polypeptide. This polypep-
tide appears to be a by-product of the translation of the at-
tenuator leader region that occurs during regulation of the
operon. Although no biological function has been de-
scribed for any of these polypeptides, an attenuator leader
peptide could serve as a source of antigenic peptide during
the host immune response to intracellular bacterial infection.
The length of the AttM polypeptide, its location at the
beginning of a polycistronic region, and the presence of
consensus sequences for the binding of RNA polymerase
and ribosomes immediately 5
 
9
 
 of the AttM translation start
site suggested that it may be a leader peptide for a transcrip-
tional attenuator. We used computer analysis to examine
the 300-bp region of DNA that included the 
 
attM
 
 gene and
the 5
 
9
 
 section of ORF 1 for formation of secondary struc-
ture (42–44). When the region encoding the AttM
polypeptide was included, a large stable hairpin structure
was predicted that would include the ribosome binding site
for ORF 1. Formation of such a structure would prevent
ribosome binding and translation (Fig. 6, 
 
top
 
). The exclu-
sion of the nucleotides encoding AttM, as would occur if
ribosome stalling were to take place in this region, elimi-
nates the large hairpin structure and frees the Shine-Dal-
garno sequence of ORF 1 for ribosome binding and initia-
tion of translation (Fig. 6, 
 
bottom
 
).
Intracellular bacterial pathogens are adapted to survive in
the host cell environment, either in the cytosol or in intra-
cellular vacuoles. To enter the host cell MHC class I pro-
Figure 5. The 23–amino acid antigenic polypeptide (AttM) is encoded
at the transcription start site of a polycistronic region. (A) The DNA se-
quence encoding the 23–amino acid polypeptide containing the antigenic
peptide sequence is immediately upstream of a polycistronic region con-
taining at least three ORFs. (B) The DNA sequence immediately 59 of
the AttM polypeptide translation start site contains an RNA polymerase
binding site consensus sequence (235, underlined bold), a Pribnow box
(210, underlined bold), and a ribosome binding site consensus sequence
(underlined italic). Immediately after the AttM stop codon is a ribosome
binding site consensus sequence for the first ORF of the polycistronic re-
gion (underlined italic). The ATG translation start sites for the AttM
polypeptide and for ORF 1 as well as the single-letter amino acid transla-
tion of the AttM polypeptide are shown (bold).
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cessing pathway, proteins derived from live intracellular
bacteria have to be secreted by the bacteria or released from
the bacterial cell surface (4). Indeed, the class I–presented
peptides identified from LM thus far are all derived from
the secreted proteins LLO, p60, and metalloprotease (45).
The LemA-derived N-formyl peptide presented by H2-
M3 is a membrane protein whose Nout–Cin topology ex-
poses the antigenic epitope to the host cell cytosol (25).
The AttM polypeptide characterized here does not appear
either to be a membrane protein or to be specifically tar-
geted for secretion by LM. However, antigenic activity can
be recovered from culture medium in which LM are
grown, indicating the AttM polypeptide is released by the
bacteria. This release of antigenic peptide is biologically
relevant, as antigen presentation occurs in cells infected
with live virulent Listeria. How the AttM polypeptide es-
capes the bacterial cytoplasm is unknown, but the small size
and the hydrophobicity of AttM may contribute to its re-
lease from the bacteria to the host cell cytosol. This would
enhance entry of peptide to the MHC class I processing
pathway of infected cells as well as protect the N-formyl
group of the peptide from bacterial deformylases.
Our findings suggest that in addition to proteins specifi-
cally targeted for secretion and membrane surface proteins,
other bacterial proteins may be accessible to the host cell
MHC class I processing pathway and serve as sources of an-
tigen. It is possible that other leader peptides serve as
sources of T cell antigens presented by MHC class I or per-
haps class II molecules. In addition, these leader peptides
could be a source of the short N-formyl bacterial peptides
that bind to chemotactic receptors found on monocytes
and neutrophils (46–48). Identification of additional leader
peptide–derived T cell antigens may establish that these
polypeptides, which are by-products of transcriptional reg-
ulation, are a source of immunologically relevant mole-
cules.
Figure 6. The 23–amino acid AttM
polypeptide may be the product of a puta-
tive transcriptional attenuator. (Top) The
nucleotide sequence encoding the AttM
polypeptide and the 59 region of ORF 1
was examined for the ability to form sec-
ondary structure using a computer program
designed to predict secondary structure
from DNA sequences based on free energy
of formation (MuFold [42–44]). Formation
of a large duplex containing the translation
start sites of the AttM polypeptide (a) and
ORF 1 (c), as well as the ribosome binding
site consensus sequence of ORF 1 (b), was
predicted. (Bottom) Eliminating the region
encoding the AttM polypeptide prevents
formation of this secondary structure. This
makes the ribosome binding site (a) and the
ATG translation start site (b) of ORF 1
available for ribosome binding and initiation
of protein translation.
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